Anifrolumab

Drug Profile

Anifrolumab

Alternative Names: Anti-IFNaR MAb - Medarex/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Medarex
  • Developer Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Systemic lupus erythematosus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • No development reported Scleroderma

Most Recent Events

  • 21 Feb 2017 Medimmune and Astrazenca completes a phase II trial in Systemic lupus erythematosus in Japan (IV) (NCT01559090)
  • 14 Feb 2017 Phase-II clinical trials in Systemic lupus erythematosus in USA, Hungary, South Korea (SC) (NCT02962960)
  • 11 Nov 2016 Immunogenicity data from the phase IIa trial in Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top